An open-label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID-19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice

The potential impact on cardiovascular morbidity and mortality have become one of the most important issues of the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 may be associated with more frequent development of acute cardiovascular complications, while patients with established cardiovascular diseases are characterized by a higher risk of severe infection and adverse in-hospital outcomes. Due to the spread scale of the pandemic, understanding the long-term cardiovascular consequences of COVID-19 is of no less importance. Inability to extrapolate available international data to the Russian population has led to the initiation of a national multicenter study (registry) of patients recovered from COVID-19 and with concomitant involvement of the cardiovascular system or with baseline severe cardiovascular diseases. The article presents its rationale, design and implications of the results for clinical practice.

1. Khan MS, Shahid I, Anker SD, et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020;18(1):403. doi:10.1186/s12916-020-01816-2.

2. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531538.

3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. doi:10.1001/jamainternmed.2020.0994.

4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585.

5. Nunez-Gil IJJ, Fernandez-Ortiz A, Maroud Eid C, et al. Underlying heart diseases and acute COVID-19 outcomes. Cardiol J. 2020. doi:10.5603/CJ.a2020.0183.

6. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and metaanalysis. Heart. 2020:heartjnl-2020-317901. doi:10.1136/heartjnl-2020-317901.

7. Working group for the surveillance and control of COVID-19 in Spain; Members of the Working group for the surveillance and control of COVID-19 in Spain. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill. 2020;25(50). doi:10.2807/1560-7917.ES.2020.25.50.2001431.

8. Sabatino J, De Rosa S, Di Salvo G, Indolfi C. Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis. PLoS One. 2020;15(8):e0237131. doi:10.1371/journal.pone.0237131.

9. Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020;25(11):4165. (In Russ.) doi:10.15829/29/1560-4071-2020-4165.

10. Wei ZY, Geng YJ, Huang J, Qian HY. Pathogenesis and management of myocardial injury in coronavirus disease 2019. Eur J Heart Fail. 2020;22(11):1994-2006. doi:10.1002/ejhf.1967.

11. Official information about the coronavirus in Russia (In Russ.) https://стопкоронавирус.рф/ (дата обращения 11.01.2021)

12. Blagova OV, Varionchik NV, Zaydenov VA, et al. Anticardiac antibodies in patients with severe and moderate COVID-19 (correlations with the clinical performance and prognosis). Russian Journal of Cardiology. 2020;25(11):4054. (In Russ.) doi:10.15829/29/1560-4071-2020-4054.

13. Glybochko P, Fomin V, Moiseev S, et al. Clinical outcomes of patients with COVID-19 admitted for respiratory support to the intensive care units in Russia. Klinicheskaya farmakologiya i terapiya. = Clin Pharmacol Ther. 2020;29(3):25-36. (In Russ.) doi:10.32756/0869-5490-2020-3-25-36.

14. https://scardio.ru/proekty/registry/registr_covid19, дата обращения 23.12.2020.

15. Roth GA, Mensah GA, Johnson CO, et al; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010.

16. Freaney PM, Shah SJ, Khan SS. COVID-19 and Heart Failure With Preserved Ejection Fraction. JAMA. 2020;324(15):1499-500. doi:10.1001/jama.2020.17445.

17. Inciardi RM, Solomon SD, Ridker PM, Metra M. Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease. J Am Heart Assoc. 2020;9(16):e017756. doi:10.1161/JAHA.120.017756.

18. Metkus TS, Sokoll LJ, Barth AS, et al. Myocardial Injury in Severe COVID-19 Compared to Non-COVID Acute Respiratory Distress Syndrome. Circulation. 2020. doi:10.1161/CIRCULATIONAHA.120.050543.

19. Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5. doi:10.1002/ejhf.1828.

20. Lindner D, Fitzek A, Brauninger H, et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020;5(11):1281-5. doi:10.1001/jamacardio.2020.3551.

21. Poteshkina NG, Lysenko MA, Kovalevskaya EA, et al. Cardiac damage in patients with COVID-19 coronavirus infection. “Arterial’naya Gipertenziya” (“Arterial Hypertension”). 2020;26(3):277-87. (In Russ.) doi:10.18705/1607-419X-2020-26-3-277-287.

22. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-73. doi:10.1001/jamacardio.2020.3557.